Kamaraj Rajamanikkam, Mejdrová Ivana, Krutakova Maria, Smutny Tomas, Škach Kryštof, Dohnalova Klara, Smutna Lucie, Nellore Dharani Sai Sreekanth, Dusek Jan, Chalupsky Karel, Hricová Jana, Kronenberger Thales, Stahl Aaron, Templin Markus, Braeuning Albert, Nencka Radim, Pavek Petr
Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
J Med Chem. 2025 Jul 24;68(14):14271-14299. doi: 10.1021/acs.jmedchem.4c03134. Epub 2025 Jul 12.
The pregnane X receptor (PXR) is an important regulator of hepatic metabolism, yet mechanistic insights into the effects of pharmacological inhibition using PXR inverse agonists or antagonists on critical genes involved in both xenobiotic and endobiotic metabolism remain limited. Here, we discovered a novel PXR inverse agonist/antagonist, MI891, which binds to the ligand-binding domain of PXR. Furthermore, we computationally designed and synthesized the proteolysis-targeting chimera molecule, MI1013, based on the PXR antagonist SPA70, which degrades PXR in HepaRG hepatic cells. Using these tools, we investigated the regulation of key PXR target genes in HepaRG cells and human hepatocytes. Our findings indicate that PXR antagonism or degradation suppresses basal and rifampicin-induced expression of selected ADME genes. Moreover, the PXR antagonists and PROTAC degrader downregulate the expression of several key genes involved in gluconeogenesis, cholesterol homeostasis, bile acid synthesis, and proliferation in hepatocyte cells, suggesting their potential therapeutic applications for metabolic diseases.
孕烷X受体(PXR)是肝脏代谢的重要调节因子,然而,对于使用PXR反向激动剂或拮抗剂进行药理抑制对参与外源性和内源性代谢的关键基因的影响,其机制性见解仍然有限。在此,我们发现了一种新型的PXR反向激动剂/拮抗剂MI891,它与PXR的配体结合域结合。此外,我们基于PXR拮抗剂SPA70通过计算设计并合成了蛋白酶靶向嵌合体分子MI1013,该分子可在HepaRG肝细胞中降解PXR。利用这些工具,我们研究了HepaRG细胞和人肝细胞中关键PXR靶基因的调控。我们的研究结果表明,PXR拮抗或降解可抑制选定的药物代谢及药物处置(ADME)基因的基础表达和利福平诱导的表达。此外,PXR拮抗剂和PROTAC降解剂下调了肝细胞中参与糖异生、胆固醇稳态、胆汁酸合成和增殖的几个关键基因的表达,表明它们在代谢性疾病中的潜在治疗应用。